The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Amphivena Therapeutics
Leadership - Amphivena Therapeutics
Stock and Other Ownership Interests - Amphivena Therapeutics
Consulting or Advisory Role - Clearside Biomedical
 
Employment - Affimed Therapeutics
Leadership - Affimed Therapeutics
Stock and Other Ownership Interests - Illumina; Perrigo; Prothena
Honoraria - Affimed Therapeutics
Research Funding - Affimed Therapeutics
Patents, Royalties, Other Intellectual Property - Affimed Therapeutics; Lynx Therapeutics; Xencor
Construction and characterization of novel CD33/CD3 tandem diabodies (TandAbs) for the treatment of acute myeloid leukemia (AML).
 
Uwe Reusch
Employment - Affimed Therapeutics
 
Kimberly H. Harrington
No Relationships to Disclose
 
Chelsea J. Gudgeon
No Relationships to Disclose
 
Ivica Fucek
Employment - Affimed Therapeutics
 
Kristina Ellwanger
Employment - Affimed Therapeutics
Patents, Royalties, Other Intellectual Property - Affimed Therapeutics
 
Michael Weichel
Employment - Affimed Therapeutics
Patents, Royalties, Other Intellectual Property - GANYMED Pharmaceuticals
 
Stefan Knackmuss
Employment - Affimed Therapeutics
Patents, Royalties, Other Intellectual Property - Affimed Therapeutics
 
Eugene Zhukovsky
No Relationships to Disclose
 
Judith A. Fox
Employment - FoxBiopharma; Sunesis Pharmaceuticals
Leadership - FoxBiopharma; Sunesis Pharmaceuticals
Stock and Other Ownership Interests - Amphivena Therapeutics; Sunesis Pharmaceuticals
Consulting or Advisory Role - Amphivena Therapeutics; Sunesis Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Sunesis Pharmaceuticals
 
Jeanmarie Guenot
No Relationships to Disclose
 
Roland B. Walter
Consulting or Advisory Role - Amphivena Therapeutics, Inc.; AstraZeneca; Covagen AG; Seagen
Research Funding - Amgen; Celator; CSL Behring; GlaxoSmithKline; Seagen; Seagen
Patents, Royalties, Other Intellectual Property - First Named Inventor: Combination of epigenetic factors and bispecific compounds targeting CD33 and CD3 in the treatment of myeloid leukemia. U.S. Patent and Trademark Office, application number 61877714; filed September 13, 2013.